LRRK2 and Parkinson disease: Although proteomic analysis has been used as a powerful tool to understand the effector mechanisms of diverse biological processes, few studies have been published that describe PD-related proteomic analyses, and none of those has focused on pNSCs differentiated from the iPSCs derived from PD patients harboring LRRK2 G2019S mutation.